---
title: "SBS released its first-quarter performance, with a net profit attributable to the parent company of 51.8252 million yuan, a year-on-year increase of 41.52%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237606683.md"
description: "According to the Zhitong Finance APP, SBS released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 597 million yuan, a year-on-year increase of 24.56%. The net profit attributable to shareholders of the listed company was 51.8252 million yuan, a year-on-year increase of 41.52%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 50.0566 million yuan, a year-on-year increase of 33.01%"
datetime: "2025-04-25T16:25:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237606683.md)
  - [en](https://longbridge.com/en/news/237606683.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237606683.md)
generator: "portal-rs"
---

# SBS released its first-quarter performance, with a net profit attributable to the parent company of 51.8252 million yuan, a year-on-year increase of 41.52%

According to the Zhitong Finance APP, SBS (002098.SZ) released its Q1 2025 report. In the first quarter, the company achieved an operating income of 597 million yuan, a year-on-year increase of 24.56%. The net profit attributable to shareholders of the listed company was 51.8252 million yuan, a year-on-year increase of 41.52%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 50.0566 million yuan, a year-on-year increase of 33.01%

### Related Stocks

- [002098.CN](https://longbridge.com/en/quote/002098.CN.md)

## Related News & Research

- [California helicopter maker wins major role in US Army pilot training](https://longbridge.com/en/news/296642218.md)
- [REG - Origin Enterprises - Holding(s) in Company](https://longbridge.com/en/news/296240027.md)
- [FirstRand Bank lists ZAR 24 million structured product notes on JSE](https://longbridge.com/en/news/296356655.md)
- [Tvardi Therapeutics: TTI-109, an oral STAT3 inhibitor, targets unmet needs in UC with promising safety and efficacy data](https://longbridge.com/en/news/296388332.md)
- [Novonesis lifts FY 2026 organic sales growth outlook to 7%-8%](https://longbridge.com/en/news/296377106.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**